Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) saw an uptick in trading volume on Thursday . 355,208 shares traded hands during mid-day trading, a decline of 34% from the previous session’s volume of 541,570 shares.The stock last traded at $14.8650 and had previously closed at $12.91.
Analyst Ratings Changes
GENB has been the subject of several analyst reports. Cantor Fitzgerald started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating for the company. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target for the company. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Finally, Piper Sandler assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.40.
View Our Latest Stock Analysis on GENB
Generate Biomedicines Price Performance
Generate Biomedicines (NASDAQ:GENB – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).
Generate Biomedicines Company Profile
Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.
Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.
Featured Stories
- Five stocks we like better than Generate Biomedicines
- Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Gen Z Trends Make These 3 Stocks Worth Watching
Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.
